← SynDRA
ASP-3026
SynDRA canonical compound SYN0038282 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | ALK |
|---|
| Mechanism of action | ALK tyrosine kinase receptor inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- ALK MODULATOR
Cross-references
Synonyms
- ASP3026
- ASP 3026
- N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine
- UNII-HP4L6MXF10
- HP4L6MXF10
- 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine
- MGGBYMDAPCCKCT-UHFFFAOYSA-N
- MLS006011176
- GTPL7740
- SCHEMBL2827739
- CHEMBL3545360
- C29H40N8O3S
- QCR-144
- EX-A140
- DTXSID90149038
- AOB6601
- MolPort-028-720-342
- BCP06436
- 2229AH
- ZINC68120928
- s8054
- CHEBI:167650
- RefChem:114603
- ALK INHIBITOR ASP3026
- DTXCID7071529
- MFCD21609265
- F6O
- orb1306963
- SCHEMBL29354559
- SCHEMBL30090555
- SCHEMBL31142530
- ASP 3026 [WHO-DD]
- GLXC-05572
- HMS3673C17
- ASP3026?
- XTB91715
- NSC765865
- NSC799336
Look up ASP-3026 in the interactive SynDRA portal →